URGN NASDAQ
UroGen Pharma Ltd.
1W: +0.1%
1M: -6.8%
3M: +10.7%
YTD: +82.3%
1Y: +132.3%
3Y: +174.3%
5Y: +144.2%
$41.40
+0.85 (+2.10%)
Weekly Expected Move ±4.8%
$37
$39
$41
$43
$45
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
7 relationships4
As Filer
counterparties named
3
As Counterparty
mentioned by others
4
Rel. Types
2024-01-02
Earliest Filing
2025-02-20
Latest Filing
acquirer: 1
target: 1
partner: 1
supplier: 1
Counterparties (Filed by URGN)
4 relationshipsCompanies named in URGN's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| UroGen Pharma, Inc. | URGN | acquirer | Purchased assets of IconOVir including product candidate ICVB-1042 | 2025-02-20 | View |
| IconOVir Bio, Inc. | — | target | Assets including product candidate ICVB-1042 were acquired by UroGen Pharma, Inc. | 2025-02-20 | View |
| Medac Gesellschaft für klinische Spezialpräparate m.b.H. | — | partner | Exclusive worldwide license and supply agreement for mitomycin formulation | 2024-01-17 | View |
| Cenexi-Laboratoires Thissen S.A. | — | supplier | Amendment to Manufacturing & Supply Agreement for mitomycin product supply and dedicated equipment installation. | 2024-01-02 | View |
Mentioned As Counterparty
3 mentionsOther companies that named URGN in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| AGEN AGENUS INC | partner | Counterparty to a License Agreement covering assets sold to Ligand. | 2024-05-30 | View |
| AGEN AGENUS INC | partner | Original licensor under a License Agreement with Agenus Inc., whose milestone payments were sold to Ligand. | 2024-05-07 | View |
| LGNZZ LIGAND PHARMACEUTICALS INC | partner | Partnered oncology program (UGN-301) subject to royalty agreement | 2024-05-07 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-20 | Other Events | View | |
| 2026-08-05 | Earnings Release; Exhibits | View | |
| 2026-06-23 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-06-02 | Other Events | View | |
| 2026-05-06 | Earnings Release; Exhibits | View | |
| 2026-03-02 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation | Agreement | View |
| 2026-03-02 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-27 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-03 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-06-13 | Other Events | View | |
| 2025-05-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-20 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities | Agreement | View |
| 2025-01-14 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2024-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-10-09 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2024-09-24 | Creation of Direct Financial Obligation | View | |
| 2024-09-13 | Departure/Election of Directors; Appointment of Officers | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR